---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-24-006916"
form_type: "8-K"
ticker: "QURE"
cik: "0001590560"
company_name: "uniQure N.V."
filed_at: "2024-05-07T23:59:59+00:00"
generated_at: "2026-06-02T18:30:49.190861+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# uniQure Q1 net loss narrows to $65.6M; cash $555.7M; advancing AMT-130 regulatory path

## Summary
- Net loss $65.6M ($1.36/sh) vs $77.2M ($1.63) in Q1 2023; revenue $8.5M vs $5.3M.
- Cash $555.7M (down from $617.9M Dec 2023); expects to fund operations into Q2 2027.
- On track for FDA interaction for AMT-130 in Q2 2024; clinical update mid-2024 with up to 3-year data on 29 patients.
- New Phase I/II trials: Fabry disease (AMT-191) enrollment begins Q2 2024; SOD1-ALS and MTLE expected Q3 2024.
- Comprehensive operational review to reduce expenses underway, completion expected mid-2024.

## SEC filing metadata
- accession: 0001558370-24-006916
- form_type: 8-K
- ticker: QURE
- cik: 0001590560
- company_name: uniQure N.V.
- filed_at: 2024-05-07T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1590560/000155837024006916/0001558370-24-006916-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1590560/000155837024006916/qure-20240507x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-24-006916
- JSON: https://secwatch.observer/filing/0001558370-24-006916.json
- Plain text: https://secwatch.observer/filing/0001558370-24-006916.txt

## Key facts
- Earnings Releases
  uniQure N.V. reported the quarter ended March 31, 2024 results: revenue $8.5 million.
  - Period: the quarter ended March 31, 2024
  - Revenue: $8.5 million
  - Result: reported results
  source text: Revenue for the three months ended March 31, 2024 was $8.5 million, compared to $5.3 million in the same period in 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1590560/000155837024006916/0001558370-24-006916-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.